Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome.

Lorenzo G, Rodríguez-Pulido M, López-Gil E, Sobrino F, Borrego B, Sáiz M, Brun A.

Antiviral Res. 2014 Sep;109:64-7. doi: 10.1016/j.antiviral.2014.06.010. Epub 2014 Jun 25.

PMID:
24973761
2.

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus.

Näslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, Weber F, Bucht G.

Virology. 2009 Mar 15;385(2):409-15. doi: 10.1016/j.virol.2008.12.012. Epub 2009 Jan 20.

3.

Inoculation of newborn mice with non-coding regions of foot-and-mouth disease virus RNA can induce a rapid, solid and wide-range protection against viral infection.

Rodríguez-Pulido M, Sobrino F, Borrego B, Sáiz M.

Antiviral Res. 2011 Dec;92(3):500-4. doi: 10.1016/j.antiviral.2011.10.005. Epub 2011 Oct 13.

PMID:
22020303
4.

A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

López-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A.

PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2309. doi: 10.1371/journal.pntd.0002309. Print 2013.

5.

Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albariño CG.

J Virol. 2012 Apr;86(8):4204-12. doi: 10.1128/JVI.07104-11. Epub 2012 Feb 15.

6.

Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.

Gowen BB, Bailey KW, Scharton D, Vest Z, Westover JB, Skirpstunas R, Ikegami T.

Antiviral Res. 2013 May;98(2):135-43. doi: 10.1016/j.antiviral.2013.03.009. Epub 2013 Mar 21.

7.

A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge.

Boshra H, Lorenzo G, Rodriguez F, Brun A.

Vaccine. 2011 Jun 15;29(27):4469-75. doi: 10.1016/j.vaccine.2011.04.043. Epub 2011 May 5.

PMID:
21549790
8.

Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.

Jansen van Vuren P, Tiemessen CT, Paweska JT.

PLoS One. 2011;6(9):e25027. doi: 10.1371/journal.pone.0025027. Epub 2011 Sep 16.

9.

Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.

Lagerqvist N, Näslund J, Lundkvist A, Bouloy M, Ahlm C, Bucht G.

Virol J. 2009 Jan 17;6:6. doi: 10.1186/1743-422X-6-6.

10.

Development of a novel, single-cycle replicable rift valley Fever vaccine.

Murakami S, Terasaki K, Ramirez SI, Morrill JC, Makino S.

PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2746. doi: 10.1371/journal.pntd.0002746. eCollection 2014 Mar.

11.

[Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].

Wang QH, Wang XJ, Hu S, Ge JY, Bu ZG.

Wei Sheng Wu Xue Bao. 2007 Aug;47(4):677-81. Chinese.

PMID:
17944371
12.

Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.

Wichgers Schreur PJ, Oreshkova N, Moormann RJ, Kortekaas J.

J Virol. 2014 Sep;88(18):10883-93. doi: 10.1128/JVI.00961-14. Epub 2014 Jul 9.

13.

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.

Busquets N, Lorenzo G, López-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, Abad FX, Rodríguez F, Bensaid A, Warimwe G, Gilbert SC, Domingo M, Brun A.

Antiviral Res. 2014 Aug;108:165-72. doi: 10.1016/j.antiviral.2014.05.020. Epub 2014 Jun 14.

PMID:
24933081
14.

Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.

Morrill JC, Mebus CA, Peters CJ.

Am J Vet Res. 1997 Oct;58(10):1104-9.

PMID:
9328662
15.

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, Holbrook MR, Worthy MN, Freiberg AN, Yilma TD.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14926-31. doi: 10.1073/pnas.1112149108. Epub 2011 Aug 23.

16.

RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice.

Rodríguez-Pulido M, Borrego B, Sobrino F, Sáiz M.

J Virol. 2011 Jul;85(13):6492-501. doi: 10.1128/JVI.00599-11. Epub 2011 Apr 27.

17.

Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.

Wichgers Schreur PJ, Kant J, van Keulen L, Moormann RJ, Kortekaas J.

Vaccine. 2015 Mar 17;33(12):1459-64. doi: 10.1016/j.vaccine.2015.01.077. Epub 2015 Feb 7.

PMID:
25665959
18.

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R.

Virology. 2010 Feb 5;397(1):187-98. doi: 10.1016/j.virol.2009.11.001. Epub 2009 Nov 24.

19.

Delivery of synthetic RNA can enhance the immunogenicity of vaccines against foot-and-mouth disease virus (FMDV) in mice.

Borrego B, Rodríguez-Pulido M, Mateos F, de la Losa N, Sobrino F, Sáiz M.

Vaccine. 2013 Sep 13;31(40):4375-81. doi: 10.1016/j.vaccine.2013.07.008. Epub 2013 Jul 13.

PMID:
23859841
20.

A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY.

Clin Vaccine Immunol. 2009 Nov;16(11):1624-32. doi: 10.1128/CVI.00182-09. Epub 2009 Sep 23.

Items per page

Supplemental Content

Write to the Help Desk